Pharma BD Deal Intelligence

AbbVie Inc. / ImmunoGen Inc.

2023 · Acquisition/Merger · $10.1B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

AbbVie acquired ImmunoGen for approximately $10.1 billion ($31.26 per share) in an all-cash merger, gaining Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate approved for FRÎ±-positive platinum-resistant ovarian cancer.

Key facts

Announced Nov 30, 2023
Closed Feb 12, 2024
Deal value $10.1B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Key assets Elahere (mirvetuximab soravtansine-gynx), ADC technology platform
Mechanism FRα-targeting antibody-drug conjugate (ADC) with DM4 maytansinoid payload

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals